Cocrystal Pharma
COCP
31 hedge funds and large institutions have $13.8M invested in Cocrystal Pharma in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
24% more funds holding
Funds holding: 25 → 31 (+6)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
16% more capital invested
Capital invested by funds: $11.9M → $13.8M (+$1.93M)
0.37% less ownership
Funds ownership: 1.61% → 1.24% (-0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$812K |
| 3 |
Renaissance Technologies
New York
|
+$145K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$88.3K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
+$85.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.48M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.15M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$147K |
| 4 |
VF
Virtu Financial
New York
|
-$66.3K |
| 5 |
Goldman Sachs
New York
|
-$66.1K |
COCP Hedge Fund Activity: Q4 2020 in Review
31 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q4 2020, worth a combined $13.8M — up 16% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new COCP positions and 5 closed out — a net gain of 6 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.28M. The largest seller was Sabby Management, exiting entirely with an estimated $2.48M sold.
- 31 institutional investors held Cocrystal Pharma (COCP) as of Q4 2020, up from 25 in Q3 2020.
- Funds reported $13.8M of Cocrystal Pharma stock for Q4 2020, up 16% quarter-over-quarter.
- 11 funds opened new Cocrystal Pharma positions in Q4 2020 and 5 closed out, a net change of +6 holders.
- The largest Cocrystal Pharma buyer in Q4 2020 was BlackRock, an estimated $1.28M added.
- The largest Cocrystal Pharma seller in Q4 2020 was Sabby Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q4 2020.